Journal of Clinical Medicine Review Utility of Minimally Invasive Technology for Inguinal Lymph Node Dissection in Penile Cancer Reza Nabavizadeh 1,* , Benjamin Petrinec 1, Andrea Necchi 2, Igor Tsaur 3, Maarten Albersen 4 and Viraj Master 1 1 Department of Urology, Emory University School of Medicine, Atlanta, GA 30322, USA;
[email protected] (B.P.);
[email protected] (V.M.) 2 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;
[email protected] 3 Department of Urology and Pediatric Urology, University Medicine Mainz, 55131 Mainz, Germany;
[email protected] 4 Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium;
[email protected] * Correspondence:
[email protected]; Tel.: +1-310-986-0966; Fax: +1-404-778-4231 Received: 9 June 2020; Accepted: 30 July 2020; Published: 3 August 2020 Abstract: Our aim is to review the benefits as well as techniques, surgical outcomes, and complications of minimally invasive inguinal lymph node dissection (ILND) for penile cancer. The PubMed, Wiley Online Library, and Science Direct databases were reviewed in March 2020 for relevant studies limited to those published in English and within 2000–2020. Thirty-one articles describing minimally invasive ILND were identified for review. ILND has an important role in both staging and treatment of penile cancer. Minimally invasive technologies have been utilized to perform ILND in penile cancer patients with non-palpable inguinal lymph nodes and intermediate to high-risk primary tumors or patients with unilateral palpable non-fixed inguinal lymph nodes measuring less than 4 cm, including videoscopic endoscopic inguinal lymphadenectomy (VEIL) and robotic videoscopic endoscopic inguinal lymphadenectomy (RVEIL).